An analysis comparing patients with psoriasis prescribed biologic agents with those prescribed nonbiologic systemic treatments found biologics were associated with a reduced risk for inflammation of the ocular surface and cornea. The Healing the Gut to Treat Psoriasis? Next Steps in Dermatology Protective Effects of BPC 157 on Liver, Kidney, and Lung Distant Organ Damage in Rats with Experimental Lower Extremity IschemiaReperfusion Injury Novel Peptide Therapy for Psoriasis Addresses Systemic Inflammation Beyond Symptom Relief Docwire News Allosteric PROTACs: Expanding the Horizon of Targeted Protein Degradation Journal of the American Chemical Society Discovery of APH02174 as a Highly Selective and Orally Bioavailable IRAK4 Degrader for the Treatment of Inflammatory Diseases Journal of Medicinal Chemistry